Cargando…
Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664759/ https://www.ncbi.nlm.nih.gov/pubmed/34906719 http://dx.doi.org/10.1016/j.cmi.2021.11.026 |
| _version_ | 1784613912032837632 |
|---|---|
| author | Dauby, Nicolas |
| author_facet | Dauby, Nicolas |
| author_sort | Dauby, Nicolas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8664759 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86647592021-12-14 Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al Dauby, Nicolas Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-04 2021-12-11 /pmc/articles/PMC8664759/ /pubmed/34906719 http://dx.doi.org/10.1016/j.cmi.2021.11.026 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Dauby, Nicolas Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al |
| title | Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al |
| title_full | Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al |
| title_fullStr | Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al |
| title_full_unstemmed | Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al |
| title_short | Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al |
| title_sort | re: ‘escmid covid-19 living guidelines: drug treatment and clinical management’ by bartoletti et al |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664759/ https://www.ncbi.nlm.nih.gov/pubmed/34906719 http://dx.doi.org/10.1016/j.cmi.2021.11.026 |
| work_keys_str_mv | AT daubynicolas reescmidcovid19livingguidelinesdrugtreatmentandclinicalmanagementbybartolettietal |